Actively Recruiting
Novel Hypoxia Imaging for Head and Neck Cancer: Imaging Phenotype for Personalized Treatment
Led by University of Utah · Updated on 2024-08-12
20
Participants Needed
1
Research Sites
74 weeks
Total Duration
On this page
Sponsors
U
University of Utah
Lead Sponsor
H
Huntsman Cancer Institute
Collaborating Sponsor
AI-Summary
What this Trial Is About
Tumor hypoxia is one of the physiological factors for treatment resistance and likely contributes to poor overall survival among patients with head and neck cancer (HNC). Identifying hypoxic features of HNC may allow the personalizing treatment plan. The investigators propose multiparametric Hypoxia MR (HMR) imaging using diffusion, perfusion, and oxygenation as non-invasive, in-vivo imaging components of a hypoxia phenotype. Assessing the hypoxia phenotypes' expression will be critically important for characterizing and predicting CRT response among patients with advanced HNC. A prospective cohort study will be conducted used multiparametric MR (MPMR) imaging correlated with treatment response assessed by 3 months fluorodeoxyglucose-positron emission tomography (FDG-PET). The image analysis approach will be developed to incorporate FDG-PET and quantitative MRI characteristics of tumor (ADC, oxygen-enhanced T1 and T2\* maps, and volume transfer constant (Ktrans) to facilitate 3D visualization of multiparametric information. This proposed study's overarching goal is to develop and validate multiparametric HMR imaging using 18F - (fluoromisonidazole) FMISO-PET and immunohistochemistry (IHC) as the standard of references.
CONDITIONS
Official Title
Novel Hypoxia Imaging for Head and Neck Cancer: Imaging Phenotype for Personalized Treatment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Newly diagnosed head and neck squamous cell carcinoma confirmed by biopsy or fine needle aspiration from the oral cavity, larynx, hypopharynx, nasopharynx, or oropharynx
- Scheduled to undergo chemoradiotherapy or surgery
- Able and willing to provide informed consent according to federal and institutional guidelines
You will not qualify if you...
- Pregnant patients
- Claustrophobia
- Presence of pacemaker, spinal stimulator, cochlear implant not compatible with MRI, or any other metallic objects in the body
- Prior treatment for head and neck cancer including surgery, radiation, or chemotherapy
- Thyroid, skin, sinonasal, or salivary gland cancer
- Abnormal kidney function with estimated glomerular filtration rate below 30 mL/min/1.73 m2
- Uncontrolled diabetes
- Patients who had FDG-PET/CT outside the study before initial treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Utah
Salt Lake City, Utah, United States, 84112
Actively Recruiting
Research Team
O
Olivia Pratt
CONTACT
N
Nousheen Alasti
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here